Zheng Quan Zhi Xing·2025-08-14 00:07Group 1 - Gao Yi Asset recently conducted research on BeiGene, indicating that the net price of Baiyueze in the U.S. has seen a mid-single-digit percentage increase, with price stability expected throughout the year [1] - Baiyueze has been approved in 75 markets, while Baizean has received approval in 47 markets, with plans for continued global regulatory expansion [1] - The revenue guidance adjustment is based on Baiyueze's leading position in the U.S. and rapid growth in Europe and other markets, leading to a diversified revenue structure [1] Group 2 - Gross margin growth is attributed to improved production efficiency of Baiyueze and Baizean, with considerations for tariff policy impacts [1] - The ORR data from the BRUIN CLL-314 study lacks statistical significance, while the ALPINE study shows Baiyueze outperforming Ibrutinib [1] - BTK CDAC is being explored for applications in immunology and inflammation, with plans for a Phase III clinical trial to start in the second half of 2025 [1] Group 3 - The Phase III trial for CDK4 inhibitors has been postponed to early 2026, with dose optimization data expected to be released this year, indicating a positive market outlook for breast cancer treatment [1] - Key Phase II trials for BTK CDAC are scheduled for 2026, with registration submissions planned [1]